Boston Scientific Corp (BSX) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Boston Scientific Corp stock $50.40, price $44.64, upside +12.9%, quality 69 out of 100. Rating: undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $35.24 – $108.14 · fair‑value band $35.28 – $65.52 · the $44.64 price screens below the $50.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Boston Scientific in your weekly email
Every Wednesday you see whether Boston Scientific is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Show moreShow less
It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems.
In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Stock analysis
Boston Scientific Corp (BSX) currently trades at $44.64, while our model-based Fair Value estimate is $50.40, implying the stock looks roughly 11% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $43.25 per share, and 6 of the 22 models we run sit above the $44.64 price.
Bear case: the Economic Profit group reads lowest at $11.64, and 16 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $35.28 (bear) to $65.52 (bull), the price of $44.64 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Boston Scientific Corp reported revenue of $20.1B in FY2025 versus $11.9B in FY2021, a compound +14.0%/yr. Reported net income was $2.9B in FY2025, compounding +29.1%/yr from FY2021.
Key figures
Market cap $66.3B Large · P/E ratio 18.8 · P/S ratio 3.15 · EPS (TTM) $2.37 · Net margin 16.6% · Return on equity 14.3% · Return on assets (EBIT) 6.7% · Operating margin 20.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (medium confidence).
What moves the price
The share trades about 57% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at 13%, BSX screens cheaper than that median.
Fair Value models
Bear$35.28Fair Value $50.40Bull$65.52
Price $44.64 · Upside +12.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.01 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 5 officers or directors bought shares worth $10.0M, most recently on Aug 25, 2026. Buying cluster
BuySusan E MoranoDirector2,040 shares at $49.22$100,409Aug 25, 2026
BuyDavid C HabigerDirector3× since May 19, 2026: 7,732 shares, avg. $52.76$407,941Aug 5, 2026
BuyMichael F MahoneyChairman, President & CEO, Director186,240 shares at $48.33$9.0MAug 3, 2026
BuyEdward J LudwigDirector2× since May 20, 2026: 8,580 shares, avg. $50.15$430,314Jul 31, 2026
BuyCheryl PegusDirector1,770 shares at $56.49$99,987May 20, 2026
SaleMichael F MahoneyChairman, President & CEO, Director160,901 shares at $93.49$15.0MFeb 2, 202610b5-1 plan
SaleArthur C ButcherEVP& Grp Pres, MedSurg & APAC17,313 shares at $101.55$1.8MDec 1, 202510b5-1 plan
SaleEllen M ZaneDirector12,891 shares at $98.28$1.3MNov 6, 202510b5-1 plan
Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+19.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
Start year 2020 (pandemic). Over 10 years: +10.4% a year
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+30.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+30.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.0% vs 22.6%, slowing
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 16%
2025 sits 77% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +3.7% a year for the price and −1.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Moderate moat from device sector margins and innovation forms the main strength, while weak signals on ownership alignment and insider activity mark the chief weakness.
Main risk: Medtronic, Abbott and Johnson & Johnson could capture more pulsed-field ablation procedures and force Boston Scientific to lower prices or accept lower margins in its electrophysiology segment.
Bull case: By accelerating its own PFA catheter launches and data-driven AI features Boston Scientific could defend or regain electrophysiology share while turning device data into new recurring revenue streams.
Bear case: If competitors continue taking share in pulsed-field ablation and liability claims from stimulator recalls mount the company might face sustained margin pressure and slower growth across its cardiovascular and neuromodulation businesses.
Boston Scientific faces lingering effects from an August cybersecurity incident that disrupted operations alongside competitive losses and market shrinkage in its electrophysiology and Watchman segments. These pressures triggered repeated guidance reductions and point to a tough 2027, even as new product launches are positioned for a rebound later. Does the pipeline deliver enough to offset the drag from those two key businesses?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 321 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+12.9% · Top 25%
Profitability
Return on equity (12 months)14.3% · Top 25%
Return on assets6.6% · Above median
Net margin (12 months)16.6% · Top 25%
Operating margin (12 months)20.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)1.4% · Below median
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)18.8× · Cheaper than median
P/B2.74× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)3.15× · Pricier than median
Price / free cash flow (fiscal year)18.1× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Boston Scientific Corp (BSX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $50.40 versus a price of $44.64, about +13% upside (undervalued).
What is the fair value of BSX?
Our model-based fair value for Boston Scientific Corp is $50.40 (as of Nov 6, 2026), built from audited fundamentals. The current price: $44.64.
What is the quality score of BSX?
Boston Scientific Corp has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Boston Scientific Corp (BSX)?
Our model-based price target is the fair value of $50.40 (as of Nov 6, 2026) from 22 valuation models. Cautious scenario $35.28, optimistic scenario $65.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Boston Scientific Corp stock forecast for 2026?
Our models put fair value at $50.40, about +13% upside versus a price of $44.64 (undervalued). Cautious scenario $35.28, optimistic scenario $65.52. The calculation is refreshed regularly with new filings.
What is the revenue of Boston Scientific Corp (BSX)?
Boston Scientific Corp reported trailing-twelve-month revenue of about $21.1B (latest available figure, as of Nov 6, 2026).
What growth is priced into Boston Scientific Corp (BSX)?
For today's price to be fair in a discounted-cash-flow model, Boston Scientific Corp would have to grow free cash flow by +6.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of BSX use?
Our models discount Boston Scientific Corp at 8.3 %: a base by market capitalisation (large), damped by beta 0.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Boston Scientific Corp that is +6.2 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Boston Scientific Corp (BSX) delivered so far?
Over the past 5 years revenue at Boston Scientific Corp grew +15.2 % a year. The price currently implies +6.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Boston Scientific Corp (BSX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Boston Scientific Corp (+6.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Boston Scientific Corp (BSX)?
The free-cash-flow yield on the price is 5.52 %: that much free cash flow Boston Scientific Corp produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Boston Scientific Corp (BSX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Boston Scientific Corp it is $50.40 per share (as of Nov 6, 2026), against a price of $44.64. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Boston Scientific Corp stock overvalued or undervalued in 2026?
As of Nov 6, 2026, BSX trades below its calculated fair value: price $44.64, fair value $50.40, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BSX?
No. The price is what the market pays today ($44.64); the fair value is what the company's own numbers justify ($50.40). For Boston Scientific Corp the two are $5.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Boston Scientific Corp worth?
The market values Boston Scientific Corp at about $66.3B (market capitalisation, as of Nov 6, 2026). Per share that is $44.64; our models calculate a fair value of $50.40 per share.
What do the bullish and bearish scenarios say about BSX?
Our models span a range for Boston Scientific Corp: cautious scenario $35.28, base $50.40, optimistic $65.52 per share (as of Nov 6, 2026, price $44.64). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BSX?
Boston Scientific Corp trades at a price-to-earnings ratio of 18.8 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $50.40 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 58.6. Other multiples: PEG 0.6, P/B 2.7, P/S 3.1, EV/EBITDA 13.2.
What is the PEG ratio of BSX?
The PEG ratio of Boston Scientific Corp is 0.62 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Boston Scientific Corp (BSX)?
Balance-sheet figures for Boston Scientific Corp (as of Nov 6, 2026): return on equity 14.3%, debt of 0.46 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is BSX from its 52-week high?
Boston Scientific Corp trades at $44.64, about 57% below its 52-week high of $104.98 and 7% above the low of $41.58 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $50.40 is for.
Which stocks are comparable to Boston Scientific Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Edwards Lifesciences Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Boston Scientific Corp stock attractive at the current price?
The data as of Nov 6, 2026: price $44.64, calculated fair value $50.40 (+13%), Quality Score 69/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BSX calculated?
We run Boston Scientific Corp through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $50.40, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Boston Scientific Corp currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Boston Scientific Corp (BSX)?
The closing price on Nov 5, 2026 was $44.64. Our model-based fair value is $50.40, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Boston Scientific Corp right now?
A fairly wide model range ($35.28 to $65.52) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Boston Scientific Corp
How large is the market capitalisation of Boston Scientific Corp (BSX)?
The market capitalisation of Boston Scientific Corp is $66.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Boston Scientific Corp (BSX)?
The price-to-sales ratio of Boston Scientific Corp is 3.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Boston Scientific Corp (BSX)?
Earnings per share at Boston Scientific Corp are $2.37 (price ÷ EPS = P/E 18.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Boston Scientific Corp (BSX)?
The net margin of Boston Scientific Corp is 16.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Boston Scientific Corp (BSX)?
The return on equity (ROE) of Boston Scientific Corp is 14.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Boston Scientific Corp (BSX)?
On an EBIT basis the return on assets of Boston Scientific Corp is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Boston Scientific Corp (BSX)?
The operating margin of Boston Scientific Corp is 20.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Boston Scientific Corp (BSX)?
Revenue at Boston Scientific Corp is growing +1.4% versus a year earlier (3y avg +16.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Boston Scientific Corp (BSX)?
Earnings per share at Boston Scientific Corp are growing −21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Boston Scientific Corp (BSX) carry?
The net debt of Boston Scientific Corp is $10.4B (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Boston Scientific Corp in the live analysis
One click puts Boston Scientific Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026